Targeted activation of ferroptosis in colorectal cancer via LGR4 targeting overcomes acquired drug resistance

Hao Zheng,Jinming Liu,Qi Cheng,Qianping Zhang,Yaoyao Zhang,Lingyu Jiang,Yan Huang,Wenlei Li,Yanping Zhao,Guo Chen,Fan Yu,Lei Liu,Yanjun Li,Xudong Liao,Lai Xu,Yi Xiao,Zhibo Zheng,Ming Li,Hongyi Wang,Gang Hu,Lei Du,Quan Chen
DOI: https://doi.org/10.1038/s43018-023-00715-8
Abstract:Acquired drug resistance is a major challenge for cancer therapy and is the leading cause of cancer mortality; however, the mechanisms of drug resistance are diverse and the strategy to specifically target drug-resistant cancer cells remains an unmet clinical issue. Here, we established a colorectal cancer-derived organoid biobank and induced acquired drug resistance by repeated low-level exposures of chemo-agents. Chemosensitivity profiling and transcriptomic analysis studies revealed that chemoresistant cancer-derived organoids exhibited elevated expression of LGR4 and activation of the Wnt signaling pathway. Further, we generated a monoclonal antibody (LGR4-mAb) that potently inhibited LGR4-Wnt signaling and found that treatment with LGR4-mAb notably sensitized drug-induced ferroptosis. Mechanistically, LGR4-dependent Wnt signaling transcriptionally upregulated SLC7A11, a key inhibitor of ferroptosis, to confer acquired drug resistance. Our findings reveal that targeting of Wnt signaling by LGR4-mAb augments ferroptosis when co-administrated with chemotherapeutic agents, demonstrating a potential opportunity to fight refractory and recurrent cancers.
What problem does this paper attempt to address?